Intellia Therapeutics Inc (LTS:0JBU)
$ 11.86 0 (0%) Market Cap: 1.22 Bil Enterprise Value: 662.64 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 51/100

Intellia Therapeutics Inc Investor Event Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $54.61 (+5.26%)
Operator

Good morning, and welcome to Intellia Therapeutics' Investor Event. My name is Drew, and I will be your conference operator today. Please be advised that this call is being recorded at the company's request. (Operator Instructions) I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.

Ian Karp
Intellia Therapeutics, Inc. - SVP of IR & Corporate Communications

Thank you, operator, and good morning, everyone. I'm pleased to welcome you to Intellia's Investor event, featuring updated interim data from the Phase I/II clinical trial of NTLA-2002.

On Saturday, Intellia issued a press release detailing these results, which were presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, also known as ACAAI, held this past week in Louisville, Kentucky. This release, along with the accompanying presentation, can be found in the investors and media convention of Intellia's website At intelliatx.com. As a reminder,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot